2015
Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN. Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 554-561. PMID: 25564105, PMCID: PMC4382671, DOI: 10.1097/qai.0000000000000510.Peer-Reviewed Original ResearchConceptsInjection-related risk behaviorsBUP/NXRisk behaviorsOpioid useNegative urinalysisTreatment strategiesInjection opioid useOpioid-dependent PWIDThrice-weekly dosingPrimary end pointBuprenorphine/naloxoneOpioid use disorderOpioid-dependent peopleEvidence-based treatmentsBehavioral drugBuprenorphine-naloxoneDose taperingOpioid injectionWeek 78HIV infectionActive treatmentHIV incidenceWeek 26Treatment optionsTreatment completion
2010
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial
Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial. Drug And Alcohol Dependence 2010, 115: 237-239. PMID: 21159452, PMCID: PMC3076517, DOI: 10.1016/j.drugalcdep.2010.09.024.Peer-Reviewed Original ResearchConceptsHIV risk reduction counselingMethadone maintenance treatmentRisk reduction counselingIllicit opiate useHIV risk behaviorsBehavioral drugReduction counselingClinical trialsOpiate useMMT servicesRisk behaviorsPrimary outcome measurePilot clinical trialTime of enrollmentSignificant baseline differencesHeroin-dependent individualsNegative test resultsMMT clinicsDaily medicationMaintenance treatmentMMT programBaseline differencesOutcome measuresMMT groupTreatment retention
2007
Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial
Chawarski MC, Mazlan M, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial. Drug And Alcohol Dependence 2007, 94: 281-284. PMID: 18164145, DOI: 10.1016/j.drugalcdep.2007.11.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentOpioid-negative urine testsHIV risk reduction counselingRisk reduction counselingHIV risk behaviorsBehavioral drugReduction counselingUrine testsClinical trialsDrug counselingRisk behaviorsSelf-reported HIV risk behaviorsTake-home dosesUrine toxicology testsHeroin-dependent individualsIndividual drug counselingSelf-reported drug useMaintenance treatmentMedication adherenceLimited counselingBuprenorphineDrug useConsecutive abstinenceToxicology testsOverall proportion